Loading
Loading
Research Overview
C-terminal fragment of HGH (residues 176–191); stimulates lipolysis and inhibits lipogenesis via β-adrenergic receptor activation without triggering IGF-1 release or affecting blood glucose, unlike full-length HGH.
AOD-9604 is a synthetic peptide fragment derived from the C-terminal region of human growth hormone (hGH), specifically engineered for use in laboratory research focused on metabolism and fat regulation. Unlike full-length growth hormone, AOD-9604 has been studied in preclinical settings for its potential to influence lipid-related processes without engaging broader growth-promoting pathways. Its structure—a short amino acid sequence—has made it a subject of interest in controlled experimental models exploring metabolic signaling.
Across in vitro and animal-based studies, AOD-9604 has been examined for its potential role in lipolysis (the breakdown of stored fats) and the inhibition of lipogenesis (the formation of new fat). Research has explored how this peptide may interact with pathways linked to fat metabolism, including those associated with β-adrenergic signaling and enzymatic activity involved in adipose tissue regulation. These investigations often focus on how AOD-9604 may affect cellular signaling, metabolic balance, and energy utilization under controlled conditions.
In addition to lipid metabolism, some experimental research has evaluated AOD-9604 in the context of cartilage and tissue-related processes, though these areas remain less defined. Studies typically examine how the peptide behaves in specific biological environments, including its interaction with receptors and downstream signaling mechanisms that may contribute to broader physiological regulation.
To support consistency in laboratory research, AOD-9604 is synthesized and stabilized for experimental use, allowing for controlled observation of its biochemical properties and activity. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, aod-9604 peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
AOD-9604 Peptide research is most relevant to protocols examining:
Targeted fat loss research without IGF-1 or blood glucose effects
Studies examining β-adrenergic lipolysis distinct from full HGH
Body composition research where GH side effects are a confounding variable
Researchers comparing AOD-9604 to HGH Fragment 176-191 mechanistically
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Effects compound in this window. Given limited human data, careful documentation is important.
Washout & review
Allow full washout (~5× half-life: ~Hours). Review data, confirm baseline recovery before any repeat protocol.
C-terminal fragment of HGH (residues 176–191); stimulates lipolysis and inhibits lipogenesis via β-adrenergic receptor activation without triggering IGF-1 release or affecting blood glucose, unlike full-length HGH.
| Parameter | Value |
|---|---|
| Dose range | 300–500 mcg/day |
| Schedule | Daily (fasted, morning) |
| Route | Subcutaneous |
| Half-life | ~Hours |
Community & Anecdotal Signal
Community signal is thin relative to its marketing presence. AOD-9604 is heavily promoted by peptide vendors, which creates a signal-to-noise problem on forums where users can't always distinguish genuine reports from marketing influence. Fat loss claims dominate the anecdotal discussion, but consistent positive outcomes are harder to find than vendor claims suggest. r/Peptides threads frequently note disappointment relative to expectations set by vendor copy. The community is more skeptical of AOD-9604 than most Growth Hormone-adjacent compounds, with several informed users citing the failed
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
